Ursprung des Netzwerks ersten Grades von Samuel Cohen
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Transition Bio, Inc.
 Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.
10
| Holding Company | Biotechnology | 10 |
Wavebreak Therapeutics Ltd.
 Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Samuel Cohen
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Medical Specialties | Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| NEUROCRINE BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
| RADIUS HEALTH, INC. | Biotechnology | Chief Executive Officer Founder Chairman Director/Board Member | |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| CONCERT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| VISTERRA INC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| ASTERIAS BIOTHERAPEUTICS INC | Biotechnology | Director/Board Member | |
Innocrin Pharmaceuticals Holdings LLC
 Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Medical Specialties | Director/Board Member | |
| MALIN CORPORATION PLC | Biotechnology | Chief Executive Officer Director/Board Member Chief Executive Officer Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Doctorate Degree | |
| Stanford University | College/University | Undergraduate Degree | |
| University of Oxford | College/University | Doctorate Degree | |
| Boston University | College/University | Graduate Degree | |
| Brandeis University | College/University | Undergraduate Degree | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Director/Board Member | |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | General Government | Corporate Officer/Principal | |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
American Academy of Neurology
 American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services American Academy of Neurology operates a professional society which represents neurologists and neuroscientists. The company was founded in 1948 and is headquartered in Minneapolis, MN. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
| BAUSCH HEALTH COMPANIES INC. | Pharmaceuticals: Other | Director/Board Member | |
Longwood Fund Management LLC
 Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Detwiler and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Reagan-udall Foundation | Director/Board Member | ||
| National Comprehensive Cancer Network Foundation | Director/Board Member | ||
| Georgetown University School of Medicine | College/University | Doctorate Degree | |
| Samaritan Health Initiatives, Inc. | Founder | ||
Brandon Point Industries Ltd.
 Brandon Point Industries Ltd. Medical/Nursing ServicesHealth Services Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland. | Medical/Nursing Services | Founder Director/Board Member | |
| DICE THER | Biotechnology | Director/Board Member | |
Verge Analytics, Inc.
 Verge Analytics, Inc. BiotechnologyHealth Technology Verge Analytics, Inc. engages in the provision of biotechnology services. It develops drugs for neurodegenerative diseases using computational genomics. The company was founded by Alice Zhang and Jason Chen in 2015 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
| POSEIDA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Celularity, Inc. (United States)
 Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Miscellaneous Commercial Services | Director/Board Member | |
Aro Biotherapeutics Co.
 Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
| KYVERNA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Financial Conglomerates | Director/Board Member | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Director/Board Member Director/Board Member | |
| BAUSCH + LOMB CORPORATION | Medical Specialties | Director/Board Member | |
| CELULARITY INC. | Miscellaneous Commercial Services | Director/Board Member | |
Totus Medicines, Inc.
 Totus Medicines, Inc. Pharmaceuticals: MajorHealth Technology Totus Medicines, Inc. manufactures drug products. The company is based in Cambridge, MA. The company was founded by Neil Dhawan, Jason Pontin. Neil Dhawan has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
Garuda Therapeutics, Inc.
 Garuda Therapeutics, Inc. BiotechnologyHealth Technology Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation. | Biotechnology | Director/Board Member | |
Incendia Therapeutics, Inc.
 Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003. | Pharmaceuticals: Major | Director/Board Member | |
| TRISALUS LIFE SCIENCES, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 42 |
| Vereinigtes Königreich | 5 |
| Irland | 4 |
| Schweiz | 2 |
| Kanada | 2 |
Sektoral
| Health Technology | 32 |
| Consumer Services | 8 |
| Commercial Services | 4 |
| Finance | 3 |
| Miscellaneous | 2 |
Operativ
| Director/Board Member | 97 |
| Corporate Officer/Principal | 29 |
| Independent Dir/Board Member | 23 |
| Founder | 22 |
| Chief Executive Officer | 18 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Andrew von Eschenbach | 33 |
| Owen Hughes | 23 |
| Shaan Gandhi | 22 |
| George Martin | 21 |
| Alfred Sandrock | 16 |
| Adrian Howd | 14 |
| Bart Henderson | 12 |
| David A. Weitz | 8 |
| Gregory L. Miller | 7 |
| Tuomas Knowles | 4 |
| Fiona Dunlevy | 4 |
| Peter H. St George-Hyslop | 3 |
| Christopher Dobson | 1 |
| Michele Vendruscolo | 1 |
| Sarah Teichmann | 1 |
- Börse
- Insiders
- Samuel Cohen
- Unternehmensverbindungen